Nantahala Capital Management’s Benitec Biopharma BNTC Stock Holding History

Nantahala Capital Management’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.9M	Buy	1,488,371 +50,000	+3%	+$593K	0.66%	43
2026 Q1	$15.3M	Buy	1,438,371 +400,000	+39%	+$4.63M	0.56%	46
2025 Q4	$14M	Buy	1,038,371 +200,276	+24%	+$2.77M	0.46%	53
2025 Q3	$11.8M	Hold	838,095	–	–	0.41%	57
2025 Q2	$9.81M	Hold	838,095	–	–	0.38%	57
2025 Q1	$10.9M	Hold	838,095	–	–	0.43%	40
2024 Q4	$10.6M	Hold	838,095	–	–	0.45%	43
2024 Q3	$7.7M	Sell	838,095 -3,300	-0.4%	-$29.5K	0.39%	53
2024 Q2	$5.88M	Buy	+841,395	New	+$6.21M	0.34%	56

Other funds holding BNTC

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nantahala Capital Management's BNTC Position: Q2 2026 in Review

Nantahala Capital Management increased its Benitec Biopharma (BNTC) stake by 3.5% in Q2 2026, buying an estimated $593K and bringing the position to 1,488,371 shares worth $19.9M. The position accounts for 0.66% of the portfolio, ranked #43.

Nantahala Capital Management first reported a position in BNTC in Q2 2024 and has held it in 9 quarters since. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

Nantahala Capital Management held 1,488,371 shares of Benitec Biopharma worth $19.9M as of Q2 2026.
Nantahala Capital Management bought 50,000 Benitec Biopharma shares in Q2 2026, an estimated $593K.
Benitec Biopharma made up 0.66% of Nantahala Capital Management's portfolio in Q2 2026, its #43 holding.
Nantahala Capital Management first reported a position in Benitec Biopharma in Q2 2024 and has held it in 9 quarters since.
87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.